Disruption of androgen signaling during puberty affects Notch pathway in rat seminiferous epithelium.
Androgen Antagonists
/ administration & dosage
Animals
Basic Helix-Loop-Helix Transcription Factors
/ genetics
Flutamide
/ administration & dosage
Gene Expression
/ drug effects
Humans
Jagged-1 Protein
/ genetics
Male
Rats, Wistar
Receptors, Androgen
/ metabolism
Receptors, Notch
/ metabolism
Repressor Proteins
/ genetics
Seminiferous Epithelium
/ drug effects
Sexual Maturation
/ physiology
Signal Transduction
/ drug effects
Testosterone
/ metabolism
Transcription Factor HES-1
/ genetics
Androgens
Notch signaling
Puberty
Testis
Journal
Reproductive biology and endocrinology : RB&E
ISSN: 1477-7827
Titre abrégé: Reprod Biol Endocrinol
Pays: England
ID NLM: 101153627
Informations de publication
Date de publication:
16 Apr 2020
16 Apr 2020
Historique:
received:
22
10
2019
accepted:
04
03
2020
entrez:
18
4
2020
pubmed:
18
4
2020
medline:
2
2
2021
Statut:
epublish
Résumé
Onset of spermatogenesis at puberty is critically dependent on the activity of hypothalamic-pituitary-gonadal axis and testosterone production by Leydig cells. The aim of this study was to examine whether activation of Notch receptors and expression of Notch ligands and effector genes in rat seminiferous epithelium are controlled by androgen signaling during puberty. Peripubertal (5-week-old) Wistar rats received injections of flutamide (50 mg/kg bw) daily for 7 days to reduce androgen receptor (AR) signaling or a single injection of ethanedimethane sulphonate (EDS; 75 mg/kg bw) to reduce testosterone production. Gene and protein expressions were analyzed by real-time RT-PCR and western blotting, respectively, protein distribution by immunohistochemistry, and steroid hormone concentrations by enzyme-linked immunosorbent assay. Statistical analyses were performed using one-way ANOVA followed by Tukey's post hoc test or by Kruskal-Wallis test, followed by Dunn's test. In both experimental models changes of a similar nature in the expression of Notch pathway components were found. Androgen deprivation caused the reduction of mRNA and protein expression of DLL4 ligand, activated forms of Notch1 and Notch2 receptors and HES1 and HEY1 effector genes (p < 0.05, p < 0.01, p < 0.001). In contrast, DLL1, JAG1 and HES5 expressions increased in seminiferous epithelium of both flutamide and EDS-treated rats (p < 0.05, p < 0.01, p < 0.001). Androgens and androgen receptor signaling may be considered as factors regulating Notch pathway activity and the expression of Hes and Hey genes in rat seminiferous epithelium during pubertal development. Further studies should focus on functional significance of androgen-Notch signaling cross-talk in the initiation and maintenance of spermatogenesis.
Sections du résumé
BACKGROUND
BACKGROUND
Onset of spermatogenesis at puberty is critically dependent on the activity of hypothalamic-pituitary-gonadal axis and testosterone production by Leydig cells. The aim of this study was to examine whether activation of Notch receptors and expression of Notch ligands and effector genes in rat seminiferous epithelium are controlled by androgen signaling during puberty.
METHODS
METHODS
Peripubertal (5-week-old) Wistar rats received injections of flutamide (50 mg/kg bw) daily for 7 days to reduce androgen receptor (AR) signaling or a single injection of ethanedimethane sulphonate (EDS; 75 mg/kg bw) to reduce testosterone production. Gene and protein expressions were analyzed by real-time RT-PCR and western blotting, respectively, protein distribution by immunohistochemistry, and steroid hormone concentrations by enzyme-linked immunosorbent assay. Statistical analyses were performed using one-way ANOVA followed by Tukey's post hoc test or by Kruskal-Wallis test, followed by Dunn's test.
RESULTS
RESULTS
In both experimental models changes of a similar nature in the expression of Notch pathway components were found. Androgen deprivation caused the reduction of mRNA and protein expression of DLL4 ligand, activated forms of Notch1 and Notch2 receptors and HES1 and HEY1 effector genes (p < 0.05, p < 0.01, p < 0.001). In contrast, DLL1, JAG1 and HES5 expressions increased in seminiferous epithelium of both flutamide and EDS-treated rats (p < 0.05, p < 0.01, p < 0.001).
CONCLUSIONS
CONCLUSIONS
Androgens and androgen receptor signaling may be considered as factors regulating Notch pathway activity and the expression of Hes and Hey genes in rat seminiferous epithelium during pubertal development. Further studies should focus on functional significance of androgen-Notch signaling cross-talk in the initiation and maintenance of spermatogenesis.
Identifiants
pubmed: 32299422
doi: 10.1186/s12958-020-00582-3
pii: 10.1186/s12958-020-00582-3
pmc: PMC7161021
doi:
Substances chimiques
Androgen Antagonists
0
Basic Helix-Loop-Helix Transcription Factors
0
Hes1 protein, rat
0
Hes5 protein, rat
0
Jag1 protein, rat
0
Jagged-1 Protein
0
Receptors, Androgen
0
Receptors, Notch
0
Repressor Proteins
0
Transcription Factor HES-1
0
Testosterone
3XMK78S47O
Flutamide
76W6J0943E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
30Subventions
Organisme : Narodowe Centrum Nauki
ID : 2017/25/B/NZ4/01037
Références
Toxicol Appl Pharmacol. 2015 Dec 15;289(3):515-24
pubmed: 26485406
PLoS One. 2013 Aug 28;8(8):e72767
pubmed: 24015274
Cancer. 1993 Dec 15;72(12 Suppl):3816-27
pubmed: 8252497
Endocrinology. 2019 Apr 1;160(4):772-781
pubmed: 30753403
Endocrinology. 1986 Feb;118(2):709-19
pubmed: 3002764
J Cell Mol Med. 2015 Jul;19(7):1624-36
pubmed: 25864518
Endocrinology. 1978 Jul;103(1):212-22
pubmed: 217637
Endocrine. 1998 Dec;9(3):253-61
pubmed: 10221590
Fertil Steril. 2005 Jan;83(1):86-94
pubmed: 15652892
Mol Endocrinol. 2013 Jan;27(1):12-24
pubmed: 23160479
Biomol Detect Quantif. 2015 Mar 11;3:9-16
pubmed: 27077029
Cell Cycle. 2013 Aug 15;12(16):2538-45
pubmed: 23907117
J Androl. 1988 Sep-Oct;9(5):343-51
pubmed: 2853150
FASEB J. 2019 Jul;33(7):8423-8435
pubmed: 30991836
Neurotox Res. 2017 Jan;31(1):77-89
pubmed: 27581038
Endocrinology. 1994 Sep;135(3):1227-34
pubmed: 8070367
Environ Toxicol. 2018 Jul;33(7):720-728
pubmed: 29663635
Toxicol In Vitro. 2017 Apr;40:324-335
pubmed: 28163245
Andrology. 2015 May;3(3):569-81
pubmed: 25873562
J Androl. 2004 Sep-Oct;25(5):692-8
pubmed: 15292098
Development. 2016 Oct 15;143(20):3700-3710
pubmed: 27621062
Stem Cells Dev. 2017 Apr 15;26(8):585-598
pubmed: 28051360
J Androl. 2001 Nov-Dec;22(6):944-52
pubmed: 11700858
Spermatogenesis. 2011 Apr;1(2):121-122
pubmed: 22319660
Nat Biotechnol. 2006 Aug;24(8):914-6
pubmed: 16900128
Reproduction. 2013 Apr 15;145(4):371-80
pubmed: 23587774
Chemosphere. 2018 May;199:182-190
pubmed: 29438945
Development. 2004 Jan;131(2):459-67
pubmed: 14701682
Reproduction. 2010 Feb;139(2):427-37
pubmed: 19903717
Cells Tissues Organs. 2017;204(5-6):283-292
pubmed: 29161703
Curr Top Dev Biol. 2014;110:285-315
pubmed: 25248480
Curr Biol. 2011 Jan 11;21(1):R40-7
pubmed: 21215938
Best Pract Res Clin Endocrinol Metab. 2015 Aug;29(4):595-605
pubmed: 26303086
EMBO Mol Med. 2019 May;11(5):
pubmed: 30940675
PLoS One. 2013 Jul 30;8(7):e71213
pubmed: 23936265
Nat Commun. 2017 Jul 11;8:16002
pubmed: 28695891
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Toxicol In Vitro. 2016 Mar;31:146-57
pubmed: 26437446
Mol Cell Biol. 2012 Jan;32(1):206-15
pubmed: 22037762
Biol Reprod. 2013 Apr 11;88(4):91
pubmed: 23467742
Arthritis Res Ther. 2012 Mar 05;14(2):R45
pubmed: 22390640
Nat Rev Mol Cell Biol. 2016 Nov;17(11):722-735
pubmed: 27507209
Tissue Cell. 2018 Jun;52:78-91
pubmed: 29857832
Endocrinology. 2011 Apr;152(4):1670-83
pubmed: 21325043
Mol Cell Endocrinol. 2012 Apr 16;352(1-2):13-25
pubmed: 21871526
BMC Cancer. 2014 Feb 11;14:78
pubmed: 24512546
FASEB J. 2012 Feb;26(2):778-87
pubmed: 22049059
Semin Cell Dev Biol. 2014 May;29:55-65
pubmed: 24598767
Andrology. 2020 Mar;8(2):457-472
pubmed: 31468707
Cancer Biol Ther. 2014 May;15(5):633-42
pubmed: 24556651
Development. 2014 Dec;141(23):4468-78
pubmed: 25406395
Int J Androl. 2010 Jun 1;33(3):507-17
pubmed: 19392831
PLoS One. 2014 Nov 20;9(11):e113365
pubmed: 25412258
Immunol Lett. 2006 Jan 15;102(1):1-9
pubmed: 16140393